Novum
Bleomycin Sulfate(Novum)은 Lugano Classification Limited Stage Hodg 표적 ADC로, Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 영역에서 개발·상용화 중입니다. 작용기전: targets and signaling pathway. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 96% (ClinicalTrials.gov NCT00722865). PK: t½ 2 h. 차별점: novel antifungals.
Lugano Classification Limited Stage Hodg
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Recruiting
NK cells in fibrotic lung diseases
vedotin, nivolumab, doxorubicin, and dacarbazin
lipid nanoparticle (INS1009) administered therapeutically in a fibrotic rat model
novel antifungals
targets and signaling pathway
T-cell-mediated tumor cell cytotoxicity
DNA damage
biomarkers in interstitial lung disease
downregulation of Cav-1 and significantly higher activation of the pro-inflammatory NF-kappaB pathway
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Novum
Bleomycin Sulfate(Novum)은 Lugano Classification Limited Stage Hodg 표적 ADC로, Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 영역에서 개발·상용화 중입니다. 작용기전: targets and signaling pathway. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 96% (ClinicalTrials.gov NCT00722865). PK: t½ 2 h. 차별점: novel antifungals.
Lugano Classification Limited Stage Hodg
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Recruiting
NK cells in fibrotic lung diseases
vedotin, nivolumab, doxorubicin, and dacarbazin
lipid nanoparticle (INS1009) administered therapeutically in a fibrotic rat model
novel antifungals
targets and signaling pathway
T-cell-mediated tumor cell cytotoxicity
DNA damage
biomarkers in interstitial lung disease
downregulation of Cav-1 and significantly higher activation of the pro-inflammatory NF-kappaB pathway
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.